scout
|Videos|September 14, 2016

The Future of XMT-1536 in Ovarian Cancer and NSCLC

Author(s)Don Bergstrom

Don Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses the future of XMT-1536 in the treatment of ovarian cancer and non-small cell lung cancer (NSCLC).

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME